FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:133-144 July 14, 2005 Number 2 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Doroshow, J. H. Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from participants in this trial to investigate whether responsiveness to erlotinib and its impact on survival were associated with expression by the tumor of epidermal growth factor receptor (EGFR) and EGFR gene amplification and mutations.

Methods EGFR expression was evaluated immunohistochemically in non–small-cell lung cancer specimens from 325 of 731 patients in the trial; 197 samples were analyzed for EGFR mutations; and 221 samples were analyzed for the number of EGFR genes.

Results In univariate analyses, survival was longer in the erlotinib group than in the placebo group when EGFR was expressed (hazard ratio for death, 0.68; P=0.02) or there was a high number of copies of EGFR (hazard ratio, 0.44; P=0.008). In multivariate analyses, adenocarcinoma (P=0.01), never having smoked (P<0.001), and expression of EGFR (P=0.03) were associated with an objective response. In multivariate analysis, survival after treatment with erlotinib was not influenced by the status of EGFR expression, the number of EGFR copies, or EGFR mutation.

Conclusions Among patients with non–small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.

Source Information

From the University Health Network, Princess Margaret Hospital Site, and the Ontario Cancer Institute, University of Toronto, Toronto (M.-S.T., A.S., J.-C.C., C.-Q.Z., S.K.-R., J.S., T.Z., N.L., P.M., G.C.S., F.A.S.); the Ottawa Health Research Institute, University of Ottawa, Ottawa (I.L., M.D., A.L.); OSI Pharmaceuticals, Boulder, Colo. (F.R.); and the National Cancer Institute of Canada Clinical Trials Group and Queen's University, Kingston, Ont., Canada (L.S., M.W., K.D., J.P.).

Drs. Sakurada, Cutz, and Zhu contributed equally to this article.

Full Text of this Article

Related Letters:

Erlotinib in Lung Cancer
Nabhan C., Bitran J. D., Takano T., Ohe Y., Pao W., Ladanyi M., Miller V. A., the Lung Cancer Oncogenome Group , Shepherd F. A., Seymour L., Tsao M.-S., Kamel-Reid S., Shepherd F. A.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:1739-1741, Oct 20, 2005. Correspondence

Assessing EGFR Mutations
Marchetti A., Felicioni L., Buttitta F., Tsao M.-S., Kamel-Reid S., Shepherd F. A.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:526-528, Feb 2, 2006. Correspondence

This article has been cited by other articles:

• Engelman, J. A., Janne, P. A. (2008). Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin. Cancer Res. 14: 2895-2899 [Abstract] [Full Text]  
• Wheatley-Price, P., Ding, K., Seymour, L., Clark, G. M., Shepherd, F. A. (2008). Erlotinib for Advanced Non-Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. JCO 26: 2350-2357 [Abstract] [Full Text]  
• Hodkinson, P. S., MacKinnon, A., Sethi, T. (2008). Targeting Growth Factors in Lung Cancer. Chest 133: 1209-1216 [Abstract] [Full Text]  
• Wang, Y.-C., Kulp, S. K., Wang, D., Yang, C.-C., Sargeant, A. M., Hung, J.-H., Kashida, Y., Yamaguchi, M., Chang, G.-D., Chen, C.-S. (2008). Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors. Cancer Res. 68: 2820-2830 [Abstract] [Full Text]  
• Seiwert, T. Y., Haraf, D. J., Cohen, E. E.W., Stenson, K., Witt, M. E., Dekker, A., Kocherginsky, M., Weichselbaum, R. R., Chen, H. X., Vokes, E. E. (2008). Phase I Study of Bevacizumab Added to Fluorouracil- and Hydroxyurea-Based Concomitant Chemoradiotherapy for Poor-Prognosis Head and Neck Cancer. JCO 26: 1732-1741 [Abstract] [Full Text]  
• Kumar, A., Petri, E. T., Halmos, B., Boggon, T. J. (2008). Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer. JCO 26: 1742-1751 [Abstract] [Full Text]  
• Rocconi, R. P., Kirby, T. O., Seitz, R. S., Beck, R., Straughn, J. M. Jr, Alvarez, R. D., Huh, W. K. (2008). Lipoxygenase Pathway Receptor Expression in Ovarian Cancer. Reproductive Sciences 15: 321-326 [Abstract]  
• Yatabe, Y., Takahashi, T., Mitsudomi, T. (2008). Epidermal Growth Factor Receptor Gene Amplification Is Acquired in Association with Tumor Progression of EGFR-Mutated Lung Cancer. Cancer Res. 68: 2106-2111 [Abstract] [Full Text]  
• D'Addario, G., Rauch, D., Stupp, R., Pless, M., Stahel, R., Mach, N., Jost, L., Widmer, L., Tapia, C., Bihl, M., Mayer, M., Ribi, K., Lerch, S., Bubendorf, L., Betticher, D. C. (2008). Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 19: 739-745 [Abstract] [Full Text]  
• Na, I. I., Byun, B. H., Kang, H. J., Cheon, G. J., Koh, J. S., Kim, C. H., Choe, D. H., Ryoo, B.-Y., Lee, J. C., Lim, S. M., Yang, S. H. (2008). 18F-Fluoro-2-Deoxy-Glucose Uptake Predicts Clinical Outcome in Patients with Gefitinib-Treated Non-Small Cell Lung Cancer. Clin. Cancer Res. 14: 2036-2041 [Abstract] [Full Text]  
• Tawbi, H., Thomas, D., Lucas, D. R., Biermann, J. S., Schuetze, S. M., Hart, A. L., Chugh, R., Baker, L. H. (2008). Epidermal Growth Factor Receptor Expression and Mutational Analysis in Synovial Sarcomas and Malignant Peripheral Nerve Sheath Tumors. The Oncologist 13: 459-466 [Abstract] [Full Text]  
• Miller, V. A., Riely, G. J., Zakowski, M. F., Li, A. R., Patel, J. D., Heelan, R. T., Kris, M. G., Sandler, A. B., Carbone, D. P., Tsao, A., Herbst, R. S., Heller, G., Ladanyi, M., Pao, W., Johnson, D. H. (2008). Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib. JCO 26: 1472-1478 [Abstract] [Full Text]  
• Ciardiello, F., Tortora, G. (2008). EGFR Antagonists in Cancer Treatment. NEJM 358: 1160-1174 [Full Text]  
• Rudin, C. M., Liu, W., Desai, A., Karrison, T., Jiang, X., Janisch, L., Das, S., Ramirez, J., Poonkuzhali, B., Schuetz, E., Fackenthal, D. L., Chen, P., Armstrong, D. K., Brahmer, J. R., Fleming, G. F., Vokes, E. E., Carducci, M. A., Ratain, M. J. (2008). Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity. JCO 26: 1119-1127 [Abstract] [Full Text]  
• Okabe, T., Okamoto, I., Tsukioka, S., Uchida, J., Iwasa, T., Yoshida, T., Hatashita, E., Yamada, Y., Satoh, T., Tamura, K., Fukuoka, M., Nakagawa, K. (2008). Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Molecular Cancer Therapeutics 7: 599-606 [Abstract] [Full Text]  
• Pinter, F., Papay, J., Almasi, A., Sapi, Z., Szabo, E., Kanya, M., Tamasi, A., Jori, B., Varkondi, E., Moldvay, J., Szondy, K., Keri, G., Dominici, M., Conte, P., Eckhardt, S., Kopper, L., Schwab, R., Petak, I. (2008). Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity for EGFR Protein by Standard Immunohistochemistry. J. Mol. Diagn. 10: 160-168 [Abstract] [Full Text]  
• Black, P. C., Brown, G. A., Inamoto, T., Shrader, M., Arora, A., Siefker-Radtke, A. O., Adam, L., Theodorescu, D., Wu, X., Munsell, M. F., Bar-Eli, M., McConkey, D. J., Dinney, C. P.N. (2008). Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells. Clin. Cancer Res. 14: 1478-1486 [Abstract] [Full Text]  
• Burris, H. III, Rocha-Lima, C. (2008). New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways. The Oncologist 13: 289-298 [Abstract] [Full Text]  
• Raponi, M., Lancet, J. E., Fan, H., Dossey, L., Lee, G., Gojo, I., Feldman, E. J., Gotlib, J., Morris, L. E., Greenberg, P. L., Wright, J. J., Harousseau, J.-L., Lowenberg, B., Stone, R. M., De Porre, P., Wang, Y., Karp, J. E. (2008). A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 111: 2589-2596 [Abstract] [Full Text]  
• Lilenbaum, R., Axelrod, R., Thomas, S., Dowlati, A., Seigel, L., Albert, D., Witt, K., Botkin, D. (2008). Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2. JCO 26: 863-869 [Abstract] [Full Text]  
• Eberhard, D. A., Giaccone, G., Johnson, B. E. (2008). Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting. JCO 26: 983-994 [Abstract] [Full Text]  
• Garcia, A. A. (2008). Small Molecules: Big Changes in the Cancer Treatment Paradigm. Journal of Pharmacy Practice 21: 17-35 [Abstract]  
• Bradbury, P. A., Heist, R. S., Kulke, M. H., Zhou, W., Marshall, A. L., Miller, D. P., Su, L., Park, S., Temel, J., Fidias, P., Sequist, L., Lynch, T. J., Wain, J. C., Shepherd, F. A., Christiani, D. C., Liu, G. (2008). A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies. Cancer Epidemiol. Biomarkers Prev. 17: 204-211 [Abstract] [Full Text]  
• Duffy, A., Kortmansky, J., Schwartz, G. K., Capanu, M., Puleio, S., Minsky, B., Saltz, L., Kelsen, D. P., O'Reilly, E. M. (2008). A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 19: 86-91 [Abstract] [Full Text]  
• de Marinis, F., Grossi, F. (2008). Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer. The Oncologist 13: 14-20 [Abstract] [Full Text]  
• Butts, C. A., Bodkin, D., Middleman, E. L., Englund, C. W., Ellison, D., Alam, Y., Kreisman, H., Graze, P., Maher, J., Ross, H. J., Ellis, P. M., McNulty, W., Kaplan, E., Pautret, V., Weber, M. R., Shepherd, F. A. (2007). Randomized Phase II Study of Gemcitabine Plus Cisplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non Small-Cell Lung Cancer. JCO 25: 5777-5784 [Abstract] [Full Text]  
• Solit, D. B., Santos, E., Pratilas, C. A., Lobo, J., Moroz, M., Cai, S., Blasberg, R., Sebolt-Leopold, J., Larson, S., Rosen, N. (2007). 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition. Cancer Res. 67: 11463-11469 [Abstract] [Full Text]  
• Holdsworth, C. H., Badawi, R. D., Manola, J. B., Kijewski, M. F., Israel, D. A., Demetri, G. D., Van den Abbeele, A. D. (2007). CT and PET: Early Prognostic Indicators of Response to Imatinib Mesylate in Patients with Gastrointestinal Stromal Tumor. Am. J. Roentgenol. 189: W324-W330 [Abstract] [Full Text]  
• Thomas, F., Rochaix, P., Benlyazid, A., Sarini, J., Rives, M., Lefebvre, J. L., Allal, B. C., Courbon, F., Chatelut, E., Delord, J.-P. (2007). Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res. 13: 7086-7092 [Abstract] [Full Text]  
• Liu, W., Wu, X., Zhang, W., Montenegro, R. C., Fackenthal, D. L., Spitz, J. A., Huff, L. M., Innocenti, F., Das, S., Cook,, E. H. Jr., Cox, N. J., Bates, S. E., Ratain, M. J. (2007). Relationship of EGFR Mutations, Expression, Amplification, and Polymorphisms to Epidermal Growth Factor Receptor Inhibitors in the NCI60 Cell Lines. Clin. Cancer Res. 13: 6788-6795 [Abstract] [Full Text]  
• Wu, W., O'Reilly, M. S., Langley, R. R., Tsan, R. Z., Baker, C. H., Bekele, N., Tang, X. M., Onn, A., Fidler, I. J., Herbst, R. S. (2007). Expression of epidermal growth factor (EGF)/transforming growth factor-{alpha} by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Molecular Cancer Therapeutics 6: 2652-2663 [Abstract] [Full Text]  
• Janne, P. A., von Pawel, J., Cohen, R. B., Crino, L., Butts, C. A., Olson, S. S., Eiseman, I. A., Chiappori, A. A., Yeap, B. Y., Lenehan, P. F., Dasse, K., Sheeran, M., Bonomi, P. D. (2007). Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non Small-Cell Lung Cancer. JCO 25: 3936-3944 [Abstract] [Full Text]  
• Arenberg, D. (2007). Bronchioloalveolar Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest 132: 306S-313S [Abstract] [Full Text]  
• Ogino, A., Kitao, H., Hirano, S., Uchida, A., Ishiai, M., Kozuki, T., Takigawa, N., Takata, M., Kiura, K., Tanimoto, M. (2007). Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non Small Cell Lung Cancer Cell Line. Cancer Res. 67: 7807-7814 [Abstract] [Full Text]  
• Godin-Heymann, N., Bryant, I., Rivera, M. N., Ulkus, L., Bell, D. W., Riese, D. J. II, Settleman, J., Haber, D. A. (2007). Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation. Cancer Res. 67: 7319-7326 [Abstract] [Full Text]  
• Perez-Soler, R. (2007). Erlotinib: Recent Clinical Results and Ongoing Studies in Non Small Cell Lung Cancer. Clin. Cancer Res. 13: 4589s-4592s [Abstract] [Full Text]  
• Wong, K.-K. (2007). HKI-272 in Non Small Cell Lung Cancer. Clin. Cancer Res. 13: 4593s-4596s [Abstract] [Full Text]  
• Bonomi, P. D., Buckingham, L., Coon, J. (2007). Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors. Clin. Cancer Res. 13: 4606s-4612s [Abstract] [Full Text]  
• Lippman, S. M., Heymach, J. V. (2007). The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention. Clin. Cancer Res. 13: 4035-4041 [Abstract] [Full Text]  
• Karamouzis, M. V., Grandis, J. R., Argiris, A. (2007). Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas. JAMA 298: 70-82 [Abstract] [Full Text]  
• Jiang, W., Freidlin, B., Simon, R. (2007). Biomarker-Adaptive Threshold Design: A Procedure for Evaluating Treatment With Possible Biomarker-Defined Subset Effect. JNCI J Natl Cancer Inst 99: 1036-1043 [Abstract] [Full Text]  
• Simon, G., Sharma, A., Li, X., Hazelton, T., Walsh, F., Williams, C., Chiappori, A., Haura, E., Tanvetyanon, T., Antonia, S., Cantor, A., Bepler, G. (2007). Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non-Small-Cell Lung Cancer. JCO 25: 2741-2746 [Abstract] [Full Text]  
• Finberg, K. E., Sequist, L. V., Joshi, V. A., Muzikansky, A., Miller, J. M., Han, M., Beheshti, J., Chirieac, L. R., Mark, E. J., Iafrate, A. J. (2007). Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features. J. Mol. Diagn. 9: 320-326 [Abstract] [Full Text]  
• Wacker, B., Nagrani, T., Weinberg, J., Witt, K., Clark, G., Cagnoni, P. J. (2007). Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies. Clin. Cancer Res. 13: 3913-3921 [Abstract] [Full Text]  
• Gridelli, C., Bareschino, M. A., Schettino, C., Rossi, A., Maione, P., Ciardiello, F. (2007). Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development. The Oncologist 12: 840-849 [Abstract] [Full Text]  
• Yamasaki, F., Johansen, M. J., Zhang, D., Krishnamurthy, S., Felix, E., Bartholomeusz, C., Aguilar, R. J., Kurisu, K., Mills, G. B., Hortobagyi, G. N., Ueno, N. T. (2007). Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt. Cancer Res. 67: 5779-5788 [Abstract] [Full Text]  
• Tsao, M.-S., Liu, G., Shepherd, F. A. (2007). Serum Proteomic Classifier for Predicting Response to Epidermal Growth Factor Receptor Inhibitor Therapy: Have We Built a Better Mousetrap?. JNCI J Natl Cancer Inst 99: 826-827 [Full Text]  
• Taguchi, F., Solomon, B., Gregorc, V., Roder, H., Gray, R., Kasahara, K., Nishio, M., Brahmer, J., Spreafico, A., Ludovini, V., Massion, P. P., Dziadziuszko, R., Schiller, J., Grigorieva, J., Tsypin, M., Hunsucker, S. W., Caprioli, R., Duncan, M. W., Hirsch, F. R., Bunn, P. A. Jr, Carbone, D. P. (2007). Mass Spectrometry to Classify Non-Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study. JNCI J Natl Cancer Inst 99: 838-846 [Abstract] [Full Text]  
• Temam, S., Kawaguchi, H., El-Naggar, A. K., Jelinek, J., Tang, H., Liu, D. D., Lang, W., Issa, J.-P., Lee, J. J., Mao, L. (2007). Epidermal Growth Factor Receptor Copy Number Alterations Correlate With Poor Clinical Outcome in Patients With Head and Neck Squamous Cancer. JCO 25: 2164-2170 [Abstract] [Full Text]  
• Agulnik, M., da Cunha Santos, G., Hedley, D., Nicklee, T., dos Reis, P. P., Ho, J., Pond, G. R., Chen, H., Chen, S., Shyr, Y., Winquist, E., Soulieres, D., Chen, E. X., Squire, J. A., Marrano, P., Kamel-Reid, S., Dancey, J., Siu, L. L., Tsao, M. S. (2007). Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib. JCO 25: 2184-2190 [Abstract] [Full Text]  
• Cappuzzo, F., Ligorio, C., Janne, P. A., Toschi, L., Rossi, E., Trisolini, R., Paioli, D., Holmes, A. J., Magrini, E., Finocchiaro, G., Bartolini, S., Cancellieri, A., Ciardiello, F., Patelli, M., Crino, L., Varella-Garcia, M. (2007). Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization-Positive/Phospho-Akt-Positive or Never Smoker Patients With Advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial. JCO 25: 2248-2255 [Abstract] [Full Text]  
• Grabinski, J. L. (2007). Pharmacogenomics of Anticancer Agents: Implications for Clinical Pharmacy Practice. Journal of Pharmacy Practice 20: 246-251 [Abstract]  
• Horiike, A., Kimura, H., Nishio, K., Ohyanagi, F., Satoh, Y., Okumura, S., Ishikawa, Y., Nakagawa, K., Horai, T., Nishio, M. (2007). Detection of Epidermal Growth Factor Receptor Mutation in Transbronchial Needle Aspirates of Non-Small Cell Lung Cancer. Chest 131: 1628-1634 [Abstract] [Full Text]  
• Taillade, L, Penault-Llorca, F, Boulet, T, Fouret, P, Michiels, S, Taranchon, E, Mountzios, G, Validire, P, Domont, J, Girard, P, Grunenwald, D, Le Chevalier, T, Soria, J-C (2007). Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 18: 1043-1050 [Abstract] [Full Text]  
• Li, T., Ling, Y.-H., Goldman, I. D., Perez-Soler, R. (2007). Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non-Small Cell Lung Cancer Cells. Clin. Cancer Res. 13: 3413-3422 [Abstract] [Full Text]  
• Frederick, B. A., Helfrich, B. A., Coldren, C. D., Zheng, D., Chan, D., Bunn, P. A. Jr., Raben, D. (2007). Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Molecular Cancer Therapeutics 6: 1683-1691 [Abstract] [Full Text]  
• Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., Parulekar, W. (2007). Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. JCO 25: 1960-1966 [Abstract] [Full Text]  
• Massarelli, E., Varella-Garcia, M., Tang, X., Xavier, A. C., Ozburn, N. C., Liu, D. D., Bekele, B. N., Herbst, R. S., Wistuba, I. I. (2007). KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer. Clin. Cancer Res. 13: 2890-2896 [Abstract] [Full Text]  
• Dubey, S., Powell, C. A. (2007). Update in Lung Cancer 2006. Am. J. Respir. Crit. Care Med. 175: 868-874 [Full Text]  
• Lynch, T. J. Jr., Kim, E. S., Eaby, B., Garey, J., West, D. P., Lacouture, M. E. (2007). Epidermal Growth Factor Receptor Inhibitor-Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management. The Oncologist 12: 610-621 [Abstract] [Full Text]  
• Yancovitz, M., Yoon, J., Mikhail, M., Gai, W., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Chapman, P. B., Osman, I., Polsky, D. (2007). Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma. J. Mol. Diagn. 9: 178-183 [Abstract] [Full Text]  
• Olejniczak, E. T., Van Sant, C., Anderson, M. G., Wang, G., Tahir, S. K., Sauter, G., Lesniewski, R., Semizarov, D. (2007). Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains. Mol Cancer Res 5: 331-339 [Abstract] [Full Text]  
• Chau, I, Cunningham, D, Hickish, T, Massey, A, Higgins, L, Osborne, R, Botwood, N, Swaisland, A (2007). Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. Ann Oncol 18: 730-737 [Abstract] [Full Text]  
• Hirsch, F., Varella-Garcia, M, Cappuzzo, F, McCoy, J, Bemis, L, Xavier, A., Dziadziuszko, R, Gumerlock, P, Chansky, K, West, H, Gazdar, A., Crino, L, Gandara, D., Franklin, W., Bunn, P. Jr (2007). Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18: 752-760 [Abstract] [Full Text]  
• Braiteh, F., Kurzrock, R. (2007). Uncommon tumors and exceptional therapies: paradox or paradigm?. Molecular Cancer Therapeutics 6: 1175-1179 [Abstract] [Full Text]  
• Toh, C.-K., Lim, W.-T. (2007). Lung cancer in never-smokers. J. Clin. Pathol. 60: 337-340 [Full Text]  
• Daniele, L., Macri, L., Schena, M., Dongiovanni, D., Bonello, L., Armando, E., Ciuffreda, L., Bertetto, O., Bussolati, G., Sapino, A. (2007). Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Molecular Cancer Therapeutics 6: 1223-1229 [Abstract] [Full Text]  
• Personeni, N. (2007). Outcome Prediction to Erlotinib in Gastroesophageal Adenocarcinomas: Can We Improve Epidermal Growth Factor Receptor and Phospho-AKT Testing?. JCO 25: 910-910 [Full Text]  
• van Zandwijk, N, van de Vijver, M. (2007). clairvoyance or reliable prediction of the future?. Ann Oncol 18: 407-408 [Full Text]  
• Jackman, D. M., Yeap, B. Y., Lindeman, N. I., Fidias, P., Rabin, M. S., Temel, J., Skarin, A. T., Meyerson, M., Holmes, A. J., Borras, A. M., Freidlin, B., Ostler, P. A., Lucca, J., Lynch, T. J., Johnson, B. E., Janne, P. A. (2007). Phase II Clinical Trial of Chemotherapy-Naive Patients >= 70 Years of Age Treated With Erlotinib for Advanced Non-Small-Cell Lung Cancer. JCO 25: 760-766 [Abstract] [Full Text]  
• Langer, C. J. (2007). Mind Your Elders: Therapeutic Implications of Epidermal Growth Factor Receptor Inhibition in Older Patients With Advanced Non-Small-Cell Lung Cancer. JCO 25: 751-753 [Full Text]  
• Okabe, T., Okamoto, I., Tamura, K., Terashima, M., Yoshida, T., Satoh, T., Takada, M., Fukuoka, M., Nakagawa, K. (2007). Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cells Bearing EGFR Gene Mutation and Amplification. Cancer Res. 67: 2046-2053 [Abstract] [Full Text]  
• Tabernero, J. (2007). The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents. Mol Cancer Res 5: 203-220 [Abstract] [Full Text]  
• Dziadziuszko, R, Holm, B, Skov, B., Osterlind, K, Sellers, M., Franklin, W., Bunn, P. Jr, Varella-Garcia, M, Hirsch, F. (2007). Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann Oncol 18: 447-452 [Abstract] [Full Text]  
• Zheng, Z., Chen, T., Li, X., Haura, E., Sharma, A., Bepler, G. (2007). DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer. NEJM 356: 800-808 [Abstract] [Full Text]  
• Wakelee, H. A., Chang, E. T., Gomez, S. L., Keegan, T. H., Feskanich, D., Clarke, C. A., Holmberg, L., Yong, L. C., Kolonel, L. N., Gould, M. K., West, D. W. (2007). Lung Cancer Incidence in Never Smokers. JCO 25: 472-478 [Abstract] [Full Text]  
• Sequist, L. V., Bell, D. W., Lynch, T. J., Haber, D. A. (2007). Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non-Small-Cell Lung Cancer. JCO 25: 587-595 [Abstract] [Full Text]  
• Schaefer, G., Shao, L., Totpal, K., Akita, R. W. (2007). Erlotinib Directly Inhibits HER2 Kinase Activation and Downstream Signaling Events in Intact Cells Lacking Epidermal Growth Factor Receptor Expression. Cancer Res. 67: 1228-1238 [Abstract] [Full Text]  
• Buck, E., Eyzaguirre, A., Barr, S., Thompson, S., Sennello, R., Young, D., Iwata, K. K., Gibson, N. W., Cagnoni, P., Haley, J. D. (2007). Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Molecular Cancer Therapeutics 6: 532-541 [Abstract] [Full Text]  
• Wang, X., Zhang, S., MacLennan, G. T., Eble, J. N., Lopez-Beltran, A., Yang, X. J., Pan, C.-X., Zhou, H., Montironi, R., Cheng, L. (2007). Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Small Cell Carcinoma of the Urinary Bladder. Clin. Cancer Res. 13: 953-957 [Abstract] [Full Text]  
• Toschi, L., Cappuzzo, F. (2007). Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. The Oncologist 12: 211-220 [Abstract] [Full Text]  
• Solit, D. B., Rosen, N. (2007). Targeting HER2 in Prostate Cancer: Where to Next?. JCO 25: 241-243 [Full Text]  
• Kato, T., Hayama, S., Yamabuki, T., Ishikawa, N., Miyamoto, M., Ito, T., Tsuchiya, E., Kondo, S., Nakamura, Y., Daigo, Y. (2007). Increased Expression of Insulin-like Growth Factor-II Messenger RNA-Binding Protein 1 Is Associated with Tumor Progression in Patients with Lung Cancer. Clin. Cancer Res. 13: 434-442 [Abstract] [Full Text]  
• Chen, H.-Y., Yu, S.-L., Chen, C.-H., Chang, G.-C., Chen, C.-Y., Yuan, A., Cheng, C.-L., Wang, C.-H., Terng, H.-J., Kao, S.-F., Chan, W.-K., Li, H.-N., Liu, C.-C., Singh, S., Chen, W. J., Chen, J. J.W., Yang, P.-C. (2007). A Five-Gene Signature and Clinical Outcome in Non-Small-Cell Lung Cancer. NEJM 356: 11-20 [Abstract] [Full Text]  
• Herbst, R. S., Lippman, S. M. (2007). Molecular Signatures of Lung Cancer -- Toward Personalized Therapy. NEJM 356: 76-78 [Full Text]  
• Borczuk, A. C., Powell, C. A. (2007). Expression Profiling and Lung Cancer Development. Proc Am Thorac Soc 4: 127-132 [Abstract] [Full Text]  
• van Zandwijk, N, Mathy, A, Boerrigter, L, Ruijter, H, Tielen, I, de Jong, D, Baas, P, Burgers, S, Nederlof, P (2007). EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol 18: 99-103 [Abstract] [Full Text]  
• Chin, T. M., Anuar, D., Soo, R., Salto-Tellez, M., Li, W. Q., Ahmad, B., Lee, S. C., Goh, B. C., Kawakami, K., Segal, A., Iacopetta, B., Soong, R. (2007). Detection of Epidermal Growth Factor Receptor Variations by Partially Denaturing HPLC. Clin. Chem. 53: 62-70 [Abstract] [Full Text]  
• Sequist, L. V., Joshi, V. A., Janne, P. A., Muzikansky, A., Fidias, P., Meyerson, M., Haber, D. A., Kucherlapati, R., Johnson, B. E., Lynch, T. J. (2007). Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.. The Oncologist 12: 90-98 [Abstract] [Full Text]